Novo Nordisk to Invest USD 506 Million to Expand Oral GLP-1 Drug Manufacturing in Ireland
New Delhi: Novo Nordisk said on Monday it will invest 432 million euros (USD 506.43 million) to expand its manufacturing facility in Athlone, Ireland.
"With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the U.S.," said Novo Nordisk's head of product supply, Kasper Bodker Mejlvang, in a statement.
The investment would improve Novo Nordisk's capacity to manufacture oral versions of its GLP-1 drugs, which include Wegovy and Ozempic, the company added.
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 2028, Novo said.
Next Story